Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-501 0.5mg
CKD-501 1mg
CKD-501 2mg
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes Mellitus, type 2, Glitazone
Eligibility Criteria
Inclusion Criteria:
- Type Ⅱ diabetes mellitus
- Fasting Plasma Glucose(FPG)≥ 126 and ≤ 270
- HbA1c between 7 and 11%
- Body mass index (BMI) in the range 21-40
- The patients who has been taking oral hypoglycemic agent or diet therapy before minimum 1 month
- Agreement with written informed consent
Exclusion Criteria:
- Type I diabetes, gestational diabetes or secondary diabetes
- Treatment with insulin(over 1month) within 3 months
- Fasting Plasma Glucose level is over 270 mg/dl
- Triglyceride level is 500 mg/dl and over
- Uncontrollable hypertension
- History of myocardial infarction, heart failure, cerebral infarction, hematencephalon or unstable angina within 6 months
- Severe hepatic dysfunction: AST, ALT, Total bilirubin, ALP level over or equal to 3 times as high as upper normal limit(UNL)
- Severe renal dysfunction: Renal failure or serum creatinine greater than 30% normal limit
- Needs treatment for acute disease, uncontrolled other diseae or diabetic complications
- In treatment concomitant drug having severe risk drug interaction with investigational drug
- History of cancer within 5 years
- History of drug abuse or alcoholism
- Hepatitis B Antigen(HBsAg) test is positive
- Treatment systemic or inhalant corticosteroids within 1 month prior to Screening
- Patient who have experience such as hypersensitivity reaction, serious adverse event or no effect by treatment with glitazones
- Fertile women who not practice contraception with appropriate methods Pregnant women or nursing mothers
- Has a contraindication to treatment investigational drug from the medical and psychogenic side
- Participated in other trial within 4 weeks Participating in other trial at present
- An impossible one who participates in clinical trial by legal or investigator's decision
Sites / Locations
- The Inje University Medical Center
- The Yeungnam University Hospital
- The Chtholic University of Korea Uijeongbu St. Mary's Hospital
- The Seoul National Univertisy Bundang Hospital
- The Wonju Christian Hospital
- The Inje University Sanggye-Paik Hospital
- The Korea University Anam Hospital
- The Samsung Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
CKD-501 0.5mg
CKD-501 1mg
CKD-501 2mg
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in fasting plasma glucose at 8 weeks
Secondary Outcome Measures
Change from baseline in Glycemic parameters after 8 weeks
Change from baseline in Lipid parameters after 8 weeks
Adverse event profile after 8 weeks of treatment
Full Information
NCT ID
NCT01030679
First Posted
December 9, 2009
Last Updated
December 14, 2009
Sponsor
Chong Kun Dang Pharmaceutical
1. Study Identification
Unique Protocol Identification Number
NCT01030679
Brief Title
Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
Official Title
To Investigate the Glycemic Control and Lipid Profile of CKD-501 Monotherapy in Patients With Type 2 Diabetes Mellitus:a Eight-week, Multicenter, Randomized, Double-blind, Parallel-Group, Placebo-controlled, Dose-ranging Study.
Study Type
Interventional
2. Study Status
Record Verification Date
December 2009
Overall Recruitment Status
Completed
Study Start Date
July 2007 (undefined)
Primary Completion Date
October 2008 (Actual)
Study Completion Date
October 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Chong Kun Dang Pharmaceutical
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to assess the safety and effectiveness of three doses of CKD-501 compared to placebo in lowering fasting plasma glucose levels in people with type 2 diabetes for 8 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Diabetes Mellitus, type 2, Glitazone
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
214 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CKD-501 0.5mg
Arm Type
Experimental
Arm Title
CKD-501 1mg
Arm Type
Experimental
Arm Title
CKD-501 2mg
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
CKD-501 0.5mg
Other Intervention Name(s)
Lobeglitazone
Intervention Description
0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
Intervention Type
Drug
Intervention Name(s)
CKD-501 1mg
Other Intervention Name(s)
Lobeglitazone
Intervention Description
1 mg/tablet, orally, 1 tablet once daily for 8 weeks
Intervention Type
Drug
Intervention Name(s)
CKD-501 2mg
Other Intervention Name(s)
Lobeglitazone
Intervention Description
2 mg/tablet, orally, 1 tablet once daily for 8 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
orally, 1 tablet once daily for 8 weeks
Primary Outcome Measure Information:
Title
Change from baseline in fasting plasma glucose at 8 weeks
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in Glycemic parameters after 8 weeks
Time Frame
8 weeks
Title
Change from baseline in Lipid parameters after 8 weeks
Time Frame
8 weeks
Title
Adverse event profile after 8 weeks of treatment
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type Ⅱ diabetes mellitus
Fasting Plasma Glucose(FPG)≥ 126 and ≤ 270
HbA1c between 7 and 11%
Body mass index (BMI) in the range 21-40
The patients who has been taking oral hypoglycemic agent or diet therapy before minimum 1 month
Agreement with written informed consent
Exclusion Criteria:
Type I diabetes, gestational diabetes or secondary diabetes
Treatment with insulin(over 1month) within 3 months
Fasting Plasma Glucose level is over 270 mg/dl
Triglyceride level is 500 mg/dl and over
Uncontrollable hypertension
History of myocardial infarction, heart failure, cerebral infarction, hematencephalon or unstable angina within 6 months
Severe hepatic dysfunction: AST, ALT, Total bilirubin, ALP level over or equal to 3 times as high as upper normal limit(UNL)
Severe renal dysfunction: Renal failure or serum creatinine greater than 30% normal limit
Needs treatment for acute disease, uncontrolled other diseae or diabetic complications
In treatment concomitant drug having severe risk drug interaction with investigational drug
History of cancer within 5 years
History of drug abuse or alcoholism
Hepatitis B Antigen(HBsAg) test is positive
Treatment systemic or inhalant corticosteroids within 1 month prior to Screening
Patient who have experience such as hypersensitivity reaction, serious adverse event or no effect by treatment with glitazones
Fertile women who not practice contraception with appropriate methods Pregnant women or nursing mothers
Has a contraindication to treatment investigational drug from the medical and psychogenic side
Participated in other trial within 4 weeks Participating in other trial at present
An impossible one who participates in clinical trial by legal or investigator's decision
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dongseop Choi, MD.,Ph.D.
Organizational Affiliation
The Korea University Anam Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
The Inje University Medical Center
City
Busan
Country
Korea, Republic of
Facility Name
The Yeungnam University Hospital
City
Daegu
Country
Korea, Republic of
Facility Name
The Chtholic University of Korea Uijeongbu St. Mary's Hospital
City
Gyeonggi-do
Country
Korea, Republic of
Facility Name
The Seoul National Univertisy Bundang Hospital
City
Gyeonggi-do
Country
Korea, Republic of
Facility Name
The Wonju Christian Hospital
City
Kangwon-Do
Country
Korea, Republic of
Facility Name
The Inje University Sanggye-Paik Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
The Korea University Anam Hospital
City
Seoul
Country
Korea, Republic of
Facility Name
The Samsung Medical Center
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs